How Does Palifermin Work? Mechanism of Action, Per the Research

Palifermin is a prescription medicine. It is a recombinant, truncated form of human keratinocyte growth factor (KGF), a member of the fibroblast growth factor family also known as FGF7. This page summarises how published pharmacology describes its molecular target and downstream signalling. It does not describe how the medicine is given, and it is not a substitute for a conversation with a prescribing clinician.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment. Any use of palifermin outside its approved labelling is investigational, and questions about whether a medicine is appropriate for a particular person belong with a prescriber.

The Molecular Target: FGFR2b

Keratinocyte growth factor signals through a specific splice variant of fibroblast growth factor receptor 2, designated FGFR2b (sometimes written KGFR). The distinguishing feature described across the literature is the distribution of that receptor: FGFR2b is expressed on epithelial cells lining the mouth, oesophagus, gastrointestinal tract, lung, bladder, skin and several glandular tissues, while haematopoietic cells and most cells of mesenchymal origin do not express it. A 2013 review of basic research and pre-clinical models described palifermin as acting on epithelial cells through this receptor to drive protection and regeneration of epithelial tissues after injury (PMID 24151975).

That restricted receptor distribution is the pharmacological rationale repeatedly cited in reviews of mucositis management: a growth signal aimed at epithelium is, in principle, separable from a growth signal aimed at tumour cells of non-epithelial lineage. A 2015 review of mucositis pathophysiology and therapeutics discussed palifermin in the context of agents that target the epithelial compartment damaged by cytotoxic therapy (PMID 26384312). Reviews nonetheless note that the receptor is present on epithelial tumours, which is why labelled use is confined to specific settings and why prescribing decisions sit with a treating clinician.

From receptor binding to cell behaviour

FGFR2b is a receptor tyrosine kinase. Ligand binding, stabilised by heparan sulfate proteoglycans, promotes receptor dimerisation and autophosphorylation, which recruits adaptor proteins and activates downstream cascades including the RAS/MAPK and PI3K/AKT pathways. In epithelial biology, those cascades are associated with cell cycle entry, survival signalling that opposes apoptosis, migration during wound closure, and differentiation toward a mature, barrier-forming phenotype. The 2013 pre-clinical review described palifermin producing epithelial protection and regeneration consistent with these proliferative and cytoprotective programmes across multiple tissue models (PMID 24151975).

Why Epithelium Matters in Mucositis

Understanding the mechanism requires understanding what cytotoxic therapy does to mucosa. Mucositis is not simply a chemical burn of the surface. A 2007 review of intestinal mucositis described a multi-phase process in which chemotherapy and radiation generate reactive oxygen species and DNA damage, activate transcription factors and pro-inflammatory signalling, cause apoptosis of basal epithelial stem cells, and only then produce the visible ulceration, with a later healing phase driven by renewed epithelial proliferation (PMID 17545794).

Palifermin's described mechanism maps onto the beginning and the end of that sequence. By stimulating basal epithelial cells before injury, it is described as thickening the epithelium and expanding the pool of progenitor cells that cytotoxic therapy will deplete; by supporting proliferation afterwards, it is described as shortening the time to re-epithelialisation. A 2025 review of management strategies for chemotherapy and radiotherapy-induced oral mucositis discussed palifermin among the agents evaluated for reducing severe oral mucositis and placed it within this mechanistic framework (PMID 39799794). A 2007 review of gastrointestinal symptoms after cytotoxic treatment similarly discussed growth factor approaches aimed at the mucosal barrier (PMID 18660719).

Additional cytoprotective elements described in the literature

Beyond proliferation, pre-clinical pharmacology has attributed several supporting actions to KGF signalling in epithelium. These include upregulation of antioxidant enzymes and detoxifying systems, increased expression of DNA repair machinery, modulation of the balance of pro-survival and pro-apoptotic proteins, and changes in cytokine handling at the mucosal surface. The 2013 review of basic and pre-clinical findings catalogued protective and regenerative effects of palifermin across epithelial injury models rather than a single pathway (PMID 24151975). A 2018 review of pharmacological modulation of radiation-induced oral mucosal complications discussed palifermin among agents acting on mucosal epithelium in this setting (PMID 29776830).

Established Versus Proposed Mechanism

It is useful to separate what is well established from what is still being characterised.

Approved Use, at Label Level

Palifermin is approved to decrease the incidence and duration of severe oral mucositis in patients with haematologic malignancies receiving myelotoxic therapy that requires haematopoietic stem cell support. Reviews of mucositis management describe that this is the setting in which the agent carries regulatory approval, and the 2025 review of oral mucositis management strategies situated palifermin among interventions assessed in that population (PMID 39799794). A 2012 review of oral mucositis prevention and treatment in children with cancer noted palifermin among agents discussed for mucositis, with paediatric application an area where evidence and labelling differ from adult practice (PMID 23413048).

Every other application described in the literature, including solid tumour radiotherapy settings, gastrointestinal mucositis and non-mucosal tissues, is investigational. Questions about whether any of this applies to an individual situation belong with a prescribing clinician, not with an educational summary.

Investigational Mechanisms Described in Animal and Laboratory Work

Immune modulation in graft-versus-host disease models

A 2008 mouse study of acute graft-versus-host disease reported that palifermin mediated immunoregulatory effects in addition to its cytoprotective effects, indicating that the agent's activity in that model was not explained by epithelial barrier protection alone (PMID 18592360). Researchers in that work framed the finding as evidence of an immune component to the response; this is animal data and has not been established as a mechanism in humans.

Thymic biology

Thymic epithelial cells express FGFR2b, which generated interest in KGF as a way to support immune reconstitution after lymphodepleting therapy. A 2019 study reported that keratinocyte growth factor impaired human thymic recovery from lymphopenia, a finding that runs counter to the simpler expectation drawn from rodent models (PMID 31063156). The study is a useful illustration that receptor expression in a tissue does not predict the direction of the physiological outcome, and that species differences matter when extrapolating KGF pharmacology.

Lung epithelium

A 2010 mouse study reported that palifermin induced alveolar maintenance programmes in emphysematous mice, consistent with FGFR2b expression on alveolar epithelium (PMID 20007933). This was an animal model of lung disease and does not describe an approved human application.

Radiation protection pharmacology

Palifermin appears in broader discussions of radioprotective and radiomitigative pharmacology because epithelial surfaces are dose-limiting tissues in radiotherapy. A 2007 review of pharmacologic approaches to radiation protection discussed growth factor strategies alongside other agents aimed at normal tissue sparing (PMID 17827457). A 2018 review of drugs used in the prevention and amelioration of radiation-induced toxic effects covered the same category of mechanisms (PMID 29221951). These reviews describe mechanistic classes; they do not establish approval for uses outside the labelled indication.

Pharmacokinetic Context That Shapes the Mechanism

Palifermin is a protein given by injection. As with other recombinant growth factors, it is cleared relatively quickly from circulation, yet the cellular response it initiates (cell cycle entry, differentiation, thickening of the epithelial layer) unfolds over a longer period than the plasma exposure itself. That mismatch between short exposure and longer biological effect is part of why the literature discusses timing relative to cytotoxic therapy as a mechanistic variable. Reviews of mucositis management note that scheduling relative to chemotherapy and radiation is part of how the agent has been studied (PMID 26384312). Specific schedules and amounts are labelling and prescribing matters and are not covered here; talk to your prescriber.

Observed Effects: What Studies Report

Because palifermin stimulates epithelium broadly, the effects reported in the literature follow the receptor distribution. Reviews of mucositis management describe skin and oral mucosal effects such as rash, erythema, pruritus, thickening of the oral mucosa, and altered taste among the reported findings associated with the agent (PMID 39799794). Reviews of mucositis pathophysiology and therapeutics have discussed tolerability considerations alongside efficacy when positioning the agent among available interventions (PMID 26384312). The 2019 study reporting impaired human thymic recovery with keratinocyte growth factor is an example of an unanticipated biological effect identified in a clinical research setting (PMID 31063156). A full safety profile is a matter for the approved product labelling and for a prescribing clinician.

What the Mechanism Does Not Explain

• Tumour biology. FGFR2b is present on epithelial tumours, so the selectivity argument that supports use in haematologic malignancy does not transfer automatically to epithelial cancers. Reviews of radiation-associated pharmacology treat normal tissue protection and tumour protection as distinct questions (PMID 17827457).
• Gastrointestinal mucositis. The gut epithelium expresses the receptor, and a 2007 review of intestinal mucositis described the mechanistic basis for growth factor interest in that compartment, while noting that management of intestinal mucositis remains a distinct clinical problem from oral mucositis (PMID 17545794).
• Immune outcomes. The animal immunoregulatory findings (PMID 18592360) and the human thymic findings (PMID 31063156) point in different directions, which is why immune effects are described as proposed rather than established.

Summary of the Mechanism

1. Palifermin is recombinant human keratinocyte growth factor (FGF7).
2. It binds FGFR2b, a receptor tyrosine kinase expressed on epithelial but not haematopoietic cells (PMID 24151975).
3. Receptor activation drives proliferation, survival and differentiation programmes in epithelial cells, described in pre-clinical models as protective and regenerative after injury (PMID 24151975).
4. In mucositis, this is framed as expanding the epithelial progenitor pool before cytotoxic injury and accelerating re-epithelialisation after it (PMID 17545794, PMID 39799794).
5. Immune, thymic and pulmonary actions remain proposed, supported largely by animal work and by human data that has not resolved in a single direction (PMID 18592360, PMID 31063156, PMID 20007933).

Anyone with a question about whether palifermin is relevant to their own care should talk to your prescriber. This page describes published pharmacology only.

References

• Managing strategies of chemotherapy and radiotherapy-induced oral mucositis (Cancer Treatment Reviews, 2025)
• Intestinal mucositis: mechanisms and management (Current Opinion in Oncology, 2007)
• Pharmacologic approaches to radiation protection (Journal of Clinical Oncology, 2007)
• Keratinocyte growth factor impairs human thymic recovery from lymphopenia (JCI Insight, 2019)
• Pharmacological modulation of radiation-induced oral mucosal complications (Cancer Radiotherapie, 2018)
• Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease (Journal of Clinical Immunology, 2008)
• Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics (Current Oncology Reports, 2015)
• Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models (Journal of Cellular and Molecular Medicine, 2013)
• Prevention and treatment of oral mucositis in children with cancer (Journal of Pediatric Pharmacology and Therapeutics, 2012)
• Cytotoxic treatment-induced gastrointestinal symptoms (Current Opinion in Supportive and Palliative Care, 2007)
• Role of drugs in the prevention and amelioration of radiation induced toxic effects (European Journal of Pharmacology, 2018)
• Palifermin induces alveolar maintenance programs in emphysematous mice (American Journal of Respiratory and Critical Care Medicine, 2010)